Genomics Stocks In Cathie Wood’s Portfolio That Are Underperforming


As of the fourth quarter of 2021, ARK Investment Management’s 13F portfolio was valued at $33 billion, according to regulatory filings. Information technology, healthcare, consumer discretionary, and communications sectors are all areas of focus for Cathie Wood’s investment portfolio. The fund’s top ten holdings account for approximately 40% of its assets. The ARK Innovation ETF, ARK Investment Management’s flagship fund, has lost 30 percent of its value this year and is more volatile than any other fund on the market. Cathie Wood defended her portfolio by claiming that ARK Invest’s stocks are “way undervalued” despite a significant setback.

Insider Monkey highlights the  10 genomics stocks in Cathie Wood’s portfolio that are underperforming. Cellectis S.A. is a French biopharmaceutical company that focuses on biotechnology, genome engineering, and cancer treatment. Genome-edited cancer immunotherapy technologies are developed and marketed by the company. With 3.7 million shares worth $291.5 million, Cathie Wood reduced her stake in Twist Bioscience Corporation by 5 percent in the fourth quarter of 2021. ARK Investment Management’s Q4 portfolio includes 0.88 percent of this stock. A loss of $0.30 per share was reported by Pacific Biosciences of California, Inc. in its fourth-quarter earnings report. Singular-molecular real-time sequencing technology has been developed by the company to enable genome assembly and genetic variation characterization of humans and other organisms. Biotechnology company Editas Medicine, Inc. specializes in gene editing and genome engineering through CRISPR–Cas9 gene editing. Cathie Wood has increased her stake in the company by 17%, and now owns 26.3 million shares, which are worth approximately $540,000,000. In the field of gene therapies and genome editing, Beam Therapeutics Inc. is a Massachusetts-based biotechnology company that relies on CRISPR and prime editing. During the previous six months, the stock price fell by 37.06 percent. For more details, click  10 Genomics Stocks In Cathie Wood’s Portfolio That Are Underperforming.